Business Description
Lexeo Therapeutics Inc
NAICS : 541715
SIC : 2834
ISIN : US52886X1072
Total Employee Number:
59Description
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 26.21 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 7.6 | |||||
3-Year EPS without NRI Growth Rate | 6.5 | |||||
3-Year FCF Growth Rate | 5.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.46 | |||||
9-Day RSI | 43.6 | |||||
14-Day RSI | 44.98 | |||||
3-1 Month Momentum % | -24.5 | |||||
6-1 Month Momentum % | -32.09 | |||||
12-1 Month Momentum % | 18.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.16 | |||||
Quick Ratio | 14.16 | |||||
Cash Ratio | 13.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -42.6 | |||||
Shareholder Yield % | -62.86 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -53.01 | |||||
ROA % | -45.35 | |||||
ROIC % | -214.08 | |||||
3-Year ROIIC % | -74.89 | |||||
ROC (Joel Greenblatt) % | -938.82 | |||||
ROCE % | -51.13 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.45 | |||||
Price-to-Tangible-Book | 1.46 | |||||
EV-to-EBIT | -1.97 | |||||
EV-to-EBITDA | -2.01 | |||||
EV-to-Forward-Revenue | 22.2 | |||||
EV-to-FCF | -1.75 | |||||
| Price-to-Net-Current-Asset-Value | 1.85 | |||||
| Price-to-Net-Cash | 1.94 | |||||
Earnings Yield (Greenblatt) % | -50.76 | |||||
FCF Yield % | -27.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LXEO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lexeo Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.45 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 77.44 | ||
| 14-Day RSI | 44.98 | ||
| 14-Day ATR ($) | 0.350477 | ||
| 20-Day SMA ($) | 4.76275 | ||
| 12-1 Month Momentum % | 18.8 | ||
| 52-Week Range ($) | 3.6 - 10.99 | ||
| Shares Outstanding (Mil) | 78.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lexeo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lexeo Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 107 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 24 days | ||
| General meeting for 2026 | 2026-06-25 10:00 | 4.89 (-1.81%) | ||
| Guidance call for 2026 | 2026-05-19 14:35 | 4.71 (-7.83%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 5.83 (+0.17%) | ||
| Annual report for 2025 | 2026-03-30 | 5.46 (-2.33%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 5.46 (-2.33%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 10:00 | 7.44 (+6.29%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 10:40 | 6.89 (+2.53%) | ||
| Guidance call for 2026 | 2026-02-12 12:30 | 6.79 (-3.41%) |
Show
Entries
Lexeo Therapeutics Inc Frequently Asked Questions
What is Lexeo Therapeutics Inc(LXEO)'s stock price today?
The current price of LXEO is $4.56. The 52 week high of LXEO is $10.99 and 52 week low is $3.60.
When is next earnings date of Lexeo Therapeutics Inc(LXEO)?
The next earnings date of Lexeo Therapeutics Inc(LXEO) is 2026-08-14 Est..
Does Lexeo Therapeutics Inc(LXEO) pay dividends? If so, how much?
Lexeo Therapeutics Inc(LXEO) does not pay dividend.
Guru Commentaries on NAS:LXEO
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Lexeo Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers